Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599737 | 0.77 | OPRM1 (0.40) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL22436666 | 0.74 | MAOB (0.40) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL22436643 | 0.74 | DRD2 (0.42) | OPRM1MAOAMAOB | |
| SCHEMBL22436647 | 0.74 | MAOB (0.41) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL23672531 | 0.72 | ACHE (0.44) | OPRM1OPRK1OPRL1HTR2A | |
| SCHEMBL28842125 | 0.69 | OPRM1 (0.44) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL2256573 | 0.67 | OPRM1 (0.67) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL2256575 | 0.67 | OPRM1 (0.67) | OPRM1OPRK1OPRL1MAOAMAOB | |
| SCHEMBL23672528 | 0.65 | HDAC4 (0.42) | OPRM1OPRK1OPRL1 | |
| SCHEMBL28719542 | 0.65 | TSHR (0.43) | OPRM1OPRK1OPRL1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344279-B | Microbiocidal picolinamide derivatives | 先正达参股股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3710429-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-05 | — | — | EP | disclosed |
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| EP-3710429-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2020-09-23 | — | — | EP | disclosed |
| CN-111344279-A | Microbicidal picolinamide derivatives | 先正达参股股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210227826-A1 | Microbiocidal Picolinamide Derivatives | CASP2, CASP1, MSR1 | OPRM1 3130/4885OPRK1 4541/4885OPRL1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.